New Oral Antibiotic for Complicated Urinary Tract Infections

Utebzi (tebipenem pivoxil) is an oral carbapenem (penem) antibacterial. The tablet contains tebipenem pivoxil hydrobromide, a prodrug that becomes tebipenem after you take it. Carbapenems are a class of antibiotics often reserved for serious or resistant infections; until this US label, carbapenems used for these infections in the United States were given by vein (IV). Utebzi is the first oral carbapenem approved in the US for this adult cUTI use.

The FDA approved NDA 215960 on 17 June 2026 (Novel Drug Approvals for 2026 table row 22; approval letter signed Peter Kim, MD, MS, Acting Deputy Director, Office of Infectious Diseases, CDER, 17 Jun 2026 09:20:37). Holder / manufactured for: GlaxoSmithKline, Durham, NC. Development and global licensing (excluding select Asian territories) involve GSK and Spero Therapeutics; NDA sponsorship was transferred to GSK. The application received Priority Review, Fast Track, and Qualified Infectious Disease Product (QIDP) designation for this indication (FDA notice). An earlier cycle received a complete response (24 Jun 2022); the 18 Dec 2025 amendment was the complete response that led to approval.

The labelled indication is narrow on purpose: adults with cUTI, including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, or Enterococcus faecalis, who have limited or no alternative oral treatment options. It is not a first-line pill for every UTI. Stewardship language on the label says use it only when infection is proven or strongly suspected to be bacterial and susceptible.

Where this is taking place

Commercial labelled door today: United States — FDA full approval for the adult cUTI / pyelonephritis line above. Infection disease, urology, hospital medicine, or another clinician managing complicated UTI writes the labelled oral course when oral alternatives are limited or absent. Prior authorization and plan coverage still apply. Authorized ≠ funded. Company materials (GSK, 17 Jun 2026) say US availability is anticipated by the end of 2026 — confirm current pharmacy stock with the clinic; approval day is not the same as every shelf stocked.

PIVOT-PO — NCT06059846 (USPI “Trial 1”) — Phase 3, global, randomized, double-blind, double-dummy, non-inferiority. Lead sponsor on ClinicalTrials.gov: Spero Therapeutics; collaborator GlaxoSmithKline. Status: COMPLETED. Enrollment 1690. Start 21 Dec 2023; primary completion 27 Jan 2025; completion 6 Feb 2025. hasExpandedAccess: false. Overall study director on the CT.gov record: David Hong, MD (Spero Therapeutics). Site countries on the record include United States, Argentina, Bosnia and Herzegovina, Brazil, Bulgaria, Croatia, Estonia, Georgia, Greece, Hungary, India, Latvia, Moldova, Poland, Romania, Serbia, Slovakia, South Africa, Turkey. Completed — not an enrolment path. Trial geography ≠ a national licence outside the US.

Outside the United States: As of this draft, no confirmed Health Canada NOC, EC marketing authorisation, MHRA licence, TGA ARTG listing, Swissmedic authorisation, NMPA decision, or PMDA/MHLW licence for Utebzi / this adult oral-tablet cUTI label. Do not treat a US blister pack as another country’s carton. The USPI’s Japan postmarketing notes refer to a fine-granules pediatric tebipenem pivoxil product used outside the US — not the US Utebzi tablet indication.

The practical door in the US is a clinician managing cUTI who has culture / susceptibility context and can decide whether labelled oral carbapenem fits — not importing IV carbapenem practice from a press headline, and not treating NCT06059846 as open enrolment.

Approval matrix

Access by country

• United States: Ask the clinician treating the complicated UTI (infectious diseases, urology, hospitalist, or experienced primary / ED follow-up). FDA-labelled 17 June 2026. Typical course: two 300 mg tablets (600 mg) every 6 hours for 7 to 10 days if kidney function is in the labelled eGFR band; kidney impairment changes the dose (see below). Swallow whole, with or without food. Finish the full course unless the clinician stops it. GSK adverse-reaction / pregnancy-exposure / Patient Information contact on the USPI: 1-888-825-5249; MedWatch 1-800-FDA-1088; more information www.gsk.com / carton QR / https://epi-pla.org. NDC blister pack 0173-0956-76 (80 tablets). No list price or copay dollars in this article. Prior authorization still applies. Children not established on this label. Company launch timing: anticipated by end of 2026 — confirm stock.

• Canada: Authorisation not confirmed. Do not mail-order a US pack as the care plan. Ask the Canadian infectious-disease / urology clinic what legal paths exist if there is no Canadian Product Monograph yet.

• European Union / United Kingdom / Australia / Switzerland / China: Authorisation not confirmed for Utebzi on sources used here. Trial sites ≠ licence.

• Japan: Do not confuse older non-Utebzi tebipenem pivoxil formulations mentioned in US postmarketing text with a US-style adult cUTI tablet licence. Utebzi MA not confirmed here.

• If your regulator has not authorised it: do not import on your own.

Who is eligible (from the US label)

This is a complicated UTI conversation — not uncomplicated cystitis treated with first-line oral agents when those still work.

United States (USPI / Patient Information, revised / issued June 2026):

• Adult (18+). Safety and effectiveness in patients younger than 18 years have not been established.
• Complicated UTI, including pyelonephritis, caused by susceptible E. coli, K. pneumoniae, Enterobacter cloacae species complex, K. oxytoca, or E. faecalis.
• Reserved for adults with limited or no alternative oral treatment options.
• Culture and susceptibility should guide therapy when available.
• Recommended dosage (eGFR 60–150 mL/min): 600 mg (two 300 mg tablets) orally every 6 hours for 7 to 10 days.
• Do not use beyond the recommended treatment duration (carnitine depletion risk with pivalate-containing drugs).
• Renal adjustment (USPI Table 1):
  • eGFR 60 to <90 mL/min: 600 mg every 6 hours
  • eGFR 30–59 mL/min: 300 mg every 6 hours
  • eGFR 15–29 mL/min: 300 mg every 12 hours
• eGFR >150 mL/min: use not recommended (predicted lower exposure / possible reduced efficacy); if used, monitor response closely.
• Hemodialysis: tebipenem is removed by hemodialysis; insufficient data to determine dosing — not a labelled home regimen from this draft.
• Contraindications: hypersensitivity to Utebzi or other beta-lactam antibacterials; primary or secondary carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency.
• Geriatrics: large share of Trial 1 patients were ≥65; no overall safety/effectiveness differences vs younger adults on the label; adjust for renal function.
• Pregnancy: human data insufficient; pregnancy safety study — report exposure to GSK 1-888-825-5249. Late-pregnancy use may cause a false-positive newborn screen for isovaleric acidemia — prompt follow-up if positive.
• Lactation: unknown in human milk; present in rat milk — discuss feeding plan.
• Not labelled for: children; viral infections; use when no bacterial infection is proven or strongly suspected; stretching the course past labelled duration to “be safe.”

What the pivotal study showed (PIVOT-PO / USPI Trial 1)

Use the USPI for a US prescription conversation. Journals and conference abstracts are supportive reading.

Trial 1 — NCT06059846 (PIVOT-PO):

• Global, randomized 1:1, double-blind, double-dummy, non-inferiority (NI margin −10% on the programme design).
• Oral Utebzi 600 mg every 6 hours vs IV imipenem-cilastatin 500 mg every 6 hours, both for 7–10 days, with renal dose adjustments and matching placebos.
• Enrolled 1690 hospitalized adults with cUTI or pyelonephritis.
• Efficacy population (micro-ITT): 929 patients with qualifying Enterobacterales in urine (± blood), pathogens susceptible to imipenem; exclusions per USPI (e.g., >2 urine organisms; baseline pathogens not susceptible to imipenem).
• Micro-ITT mix (USPI): 22% cUTI with pyelonephritis, 43% cUTI without pyelonephritis, 34% pyelonephritis; median age 68; 58% female; 7% concomitant bacteremia at baseline; most enrolled from Central and Eastern Europe.
• Primary: composite of clinical cure + microbiological response at test-of-cure (Day 17 ± 2).

USPI Table 5 (micro-ITT, TOC):

Subgroups by age, sex, renal function, diagnosis, and instrumentation were generally consistent with the overall result on the label. Among baseline bacteremia cases, composite response was 40.6% (13/32) Utebzi vs 61.8% (21/34) imipenem-cilastatin — a small subgroup the clinic should read carefully, not a separate labelled indication.

Pathogen-level composite rates (USPI Table 6, selected): E. coli 58.0% vs 61.2%; K. pneumoniae 54.3% vs 56.6%; E. faecalis (with Enterobacterales co-pathogen rules) 43.5% vs 50.0%. ESBL+ Enterobacterales composite rates were described as consistent with the overall population (52.2% Utebzi; 56.8% imipenem-cilastatin).

Safety population: 843 received oral Utebzi; 844 received IV imipenem-cilastatin; median duration ~7.5–7.6 days. Discontinuations for adverse reactions: 0.6% vs 0.8%.

How it is taken (US label — keep this exact)

• Strength: 300 mg film-coated tablets — green, round, biconvex, debossed “TBP” / “300”.
• Usual adult dose (eGFR 60–150): 600 mg = two tablets every 6 hours for 7 to 10 days.
• Take with or without food. Swallow whole.
• Missed dose: take as soon as possible; do not double a dose to catch up.
• Store 20–25 °C (excursions 15–30 °C). Blister pack of 80 tablets, NDC 0173-0956-76.
• Tell the clinician about kidney problems, seizure history, carnitine disorders, pregnancy/breastfeeding plans, and medicines such as probenecid, valproic acid / divalproex, and other pivalate-generating drugs.

Safety (USPI)

Contraindications: beta-lactam hypersensitivity; carnitine deficiency / relevant inborn errors of metabolism.

Warnings and precautions:

• Serious hypersensitivity / anaphylaxis (beta-lactam / carbapenem class).
• Seizures and other CNS reactions — higher concern with CNS disorders and/or poor kidney function; continue anticonvulsants if already prescribed for seizures.
• Valproic acid / divalproex: avoid — carbapenems can lower valproate levels and raise breakthrough-seizure risk.
• Carnitine depletion from pivalate — do not extend beyond labelled duration; watch for hypoglycemia, fatigue, muscle aches/weakness, fainting, seizures, confusion; generally avoid other pivalate-generating drugs.
• Clostridioides difficile infection — evaluate diarrhea (can occur weeks after antibiotics).
• False-positive newborn isovaleric acidemia screen if used in late pregnancy.
• Stewardship: not for viruses; finish the prescribed course.

Most common adverse reactions (≥1% on Utebzi in Trial 1, USPI Table 2):

Less common (<1%): vomiting, dyspepsia, Candida infections, rash/pruritus/urticaria. Japan postmarketing (other formulation, pediatrics) noted hypoglycemia with hypocarnitinemia and seizures — relevant background for the carnitine contraindication, not a US pediatric label.

Drug interactions (high level): OAT1/OAT3 inhibitors (e.g., probenecid) — generally avoid / monitor; valproate — avoid; other pivalate drugs — generally avoid.

Report suspected adverse reactions to GSK 1-888-825-5249 or FDA MedWatch 1-800-FDA-1088.

No boxed warning on the USPI retrieved for this draft. That is not “no risk” — allergy, CNS/seizure class effects, carnitine, C. difficile, and renal dosing are the main labelled safety story.

Research team (source-only)

Names and roles as they appear on primary sources — not a clinic directory.

• GlaxoSmithKline LLC (GSK) — NDA 215960 applicant / manufactured for (Durham, NC on USPI). Patient / AE / pregnancy contact: 1-888-825-5249.
• Spero Therapeutics — ClinicalTrials.gov lead sponsor, PIVOT-PO; development partner under GSK exclusive licence (ex select Asian territories).
• Angela Natilla, PhD — Director, Global Regulatory Strategy, GSK; addressee on the NDA approval letter (corporate regulatory contact, not a treating clinic).
• David Hong, MD — Study Director, Spero Therapeutics, on the NCT06059846 CT.gov record.
• Peter Kim, MD, MS — Acting Deputy Director, Office of Infectious Diseases, CDER — signed the 17 Jun 2026 approval letter.
• Deborah Kim, PharmD, RAC — FDA Senior Regulatory Project Manager named on the approval letter (agency contact, not a patient hotline).
• BARDA — US federal contract support for development cited in GSK materials (HHSO100201800015C; HHSO100201300011C) — funding context, not a prescription desk.

Site-level hospital phone numbers are not listed here — ask your own infection / urology clinician.

How to talk to a doctor

Bring the brand, the INN, the NCT number, and the US label:

1. “I have a complicated UTI / pyelonephritis. The FDA labelled Utebzi (tebipenem pivoxil) on 17 June 2026 as an oral carbapenem for adults with limited or no alternative oral options. Is that a fit given my culture results?”
2. “The labelled dose is 600 mg (two 300 mg tablets) every 6 hours for 7–10 days if my eGFR is in range. What is my kidney-adjusted dose, and how long should I take it?”
3. “PIVOT-PO (NCT06059846) showed oral Utebzi was non-inferior to IV imipenem-cilastatin on the composite cure endpoint (~58.5% vs 60.2%). Can we use an oral course instead of (or to step down from) IV carbapenem?”
4. “I do / do not have a history of penicillin / carbapenem allergy, seizures, or carnitine problems. I do / do not take valproate or probenecid.”
5. “Side effects to watch: diarrhea (including possible C. difficile), headache, nausea, stomach pain, liver-enzyme changes. When should I call about watery or bloody diarrhea?”
6. “I understand this is reserved when oral alternatives are limited — not a routine first antibiotic for simple cystitis.”
7. If outside the US: “Is there a licence in this country yet? I will not mail-order a US blister pack.”
8. “Prior authorization — what does my plan need (cultures, prior oral failures, stewardship attestation)?”

Canada zoom: not confirmed

There is no retrieved Health Canada Notice of Compliance or DIN for Utebzi / tebipenem pivoxil adult cUTI tablets on the sources used for this draft. US FDA approval does not create a Canadian Product Monograph. Do not treat cross-border mail-order as the care plan. Ask a Canadian ID / urology clinician what legal options exist while waiting for any future Canadian decision.

Bottom line

Utebzi (tebipenem pivoxil) is the first FDA-approved oral carbapenem — labelled 17 June 2026 for adults with cUTI including pyelonephritis caused by listed susceptible bacteria when oral alternatives are limited or gone. Dose is typically 600 mg by mouth every 6 hours for 7–10 days, with renal adjustments. PIVOT-PO (NCT06059846) showed non-inferiority to IV imipenem-cilastatin on the labelled composite endpoint. Main safety watch: allergy, seizures/CNS class effects, carnitine depletion, C. difficile, and kidney dosing. US primary; other regulators not confirmed for this product/indication here. The practical door is a cUTI clinician and a labelled US prescription — completed Phase 3 is not an enrolment path. Authorized is not funded.

---

Primary sources

1. FDA — FDA approves first oral carbapenem therapy for complicated urinary tract infections (notice; Priority Review, Fast Track, QIDP) — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections
2. FDA Prescribing Information PDF, NDA 215960, label 215960Origs000lbl.pdf, Revised 6/2026 — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215960Origs000lbl.pdf
3. FDA NDA approval letter, NDA 215960, signed Peter Kim, MD, MS, 17 Jun 2026 — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215960Orig1s000ltr.pdf
4. FDA Novel Drug Approvals for 2026 — Utebzi / tebipenem pivoxil / 6/17/2026 (row 22) — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
5. GSK US press release — Utebzi (tebipenem pivoxil) approved in the US for adults with cUTIs, 17 Jun 2026 — https://us.gsk.com/en-us/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/
6. ClinicalTrials.gov PIVOT-PO NCT06059846 — https://clinicaltrials.gov/study/NCT06059846
7. GSK — Positive PIVOT-PO phase III data (IDWeek 2025 programme communication) — https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/
8. Open Forum Infectious Diseases abstract — Oral Tebipenem Pivoxil Hydrobromide versus Intravenous Imipenem-Cilastatin… PIVOT-PO (journal abstract; not the label) — https://doi.org/10.1093/ofid/ofaf695.003